Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age To the Editor: In the United States, the incidence ratio of basal cell carcinomas (BCCs) to cutaneous squamous cell carcinomas (SCCs) is traditionally taught as 4:1.
1,2 However, the origin of this ratio is unclear, as earlier US-based studies ( published before 1989) report an incidence ratio ranging from 1.4:1 to 9:1. 3 Recently, Rogers and colleagues 4 reported a 1:1 incidence ratio of BCC:SCC using procedural data from the predominantly Caucasian, elderly Medicare fee-for-service population. To evaluate this incidence ratio across all age groups, we performed a retrospective review of BCC and SCC incidence in a northern Californian population. Furthermore, to corroborate our findings, we assessed the lifetime prevalence of BCC and SCC in a larger independent cohort. This study was approved by the institutional review board of Stanford University.
To calculate incidences, we analyzed all 8032 diagnostic BCC and SCC dermatopathology reports collected at Stanford Healthcare from 2005 to 2015 (set 1). Patients of all ethnicities were included and 86% were Caucasian. To calculate lifetime prevalence, we used self-reported BCC and SCC cases from 23andMe (set 2), totaling 12,945 patients with BCC, 6579 patients with SCC, and over 250,000 control subjects, all of whom were Caucasian. Accuracy of self-reported answers was previously validated via comparison with medical records in a subset of patients. 5 Analysis of set 1 demonstrates an overall BCC:SCC incidence ratio of 1.4:1 (Table I ). In the younger age groups, BCCs heavily outnumber SCCs; however, the ratio equalizes as age increases, reaching 1.1:1 in the age group older than 60 years. Set 2 reveals a lifetime prevalence of 11% and 6% for BCC and SCC, respectively, in Caucasians older than 60 years (Table II) , consistent with prior studies. 6 As expected for low-mortality diseases, the lifetime prevalence of these cancers increases steadily with age.
The overall BCC:SCC incidence ratio of 1.4:1 in this predominantly Caucasian population is significantly lower than 4:1 and corroborates the recent finding of a 1:1 ratio among Medicare beneficiaries. 4 Because these cancers have low mortality and can occur multiple times per individual, the overall lifetime prevalence ratio is expected to approximate the overall incidence ratio yet also demonstrate a slight skew away from the cancer with the greater net increase in incidence across age groups (SCC in this case). Hence, our finding of a 2.0:1 overall lifetime prevalence ratio in an independent cohort substantiates our incidence results.
Notably, we included both invasive SCC and SCC in situ under the term ''SCC.'' If we exclude SCC in situ from set 1, then the BCC:SCC ratio in the group older than 60 years increases to 1.8:1, which is greater than the corresponding value of 1.2:1 found in the Medicare study. 4 This difference is unsurprising considering that SCC in situ is often treated nonsurgically (and is consequently underreported in Medicare claims data). In addition, the high average ultraviolet index in California likely influenced rates of SCC and SCC in situ in our study.
Strengths of this study include large sample size for lifetime prevalence estimates and incidences based on dermatopathology reports. Overall, we demonstrate that the BCC:SCC incidence ratio is much closer to 1:1 than 4:1ethus, clinicians should increase their index of suspicion for SCC, particularly when evaluating older patients. The detection of human papillomaviruse16 in squamous cell carcinoma of the nail unit: A case series
To the Editor: The correlation between human papillomavirus (HPV) and squamous cell carcinoma (SCC) of the skin and adnexa is still controversial.
1
The detection of the virus has been described in several case series of nail unit SCC. 2, 3 This study aimed to evaluate the presence of HPV in a series of 41 cases of nail unit SCC referred to our dermatology skin cancer unit between January 2006 and December 2014.
The study was carried out on residual biopsy sections after diagnostic analysis in the course of institutional diagnostic services and was exempted from institutional review board review.
The INNO-LiPA HPV Genotyping Extra assay (Fujirebio, Pomezia, Italia Srl) was used to detect 28 mucosal HPV, including 18 high-risk and probable high-risk HPV (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82), 7 low-risk HPV (6, 11, 40, 43, 44, 54, 70) , and 3 undetermined-risk HPV (69, 71, 74). All samples were amplified in real-time polymerase chain reaction (PCR) with a primer pair specific for the E6 region of HPV-16 to avoid false negatives because of the loss of the L1 region, resulting from viral integration in cancer cells. Finally, a nested PCR (FAP nested PCR) was used for the detection of a broad spectrum of cutaneous -HPV; a consensus outer primer pair FAP 59/6415 and a consensus inner primer pair FAP 6085/6319 were used for end point PCR amplification. Table I shows patients' demographic data, and clinical and histopathologic characteristics of the 
